Epithelial Immunomodulation by Aerosolized Toll-like Agonists Prevents Allergic Lung Inflammation by Reducing Th2 Polarization
M. Ntita(The University of Texas MD Anderson Cancer Center), E.E. Scott(The University of Texas MD Anderson Cancer Center), M.K. Longmire(The University of Texas MD Anderson Cancer Center), V. Kulkarni(The University of Texas MD Anderson Cancer Center), Jezreel Pantaleón García(The University of Texas MD Anderson Cancer Center), Yinghong Wang(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|416
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
|Cancer Cell|2022|338